Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PTEN R130* MK2206 follicular thyroid carcinoma sensitive detail...
RET fusion Selpercatinib follicular thyroid carcinoma sensitive detail...
RET fusion Pralsetinib follicular thyroid carcinoma sensitive detail...
BRAF V600E Dabrafenib follicular thyroid carcinoma sensitive detail...
BRAF V600E Vemurafenib follicular thyroid carcinoma sensitive detail...
BRAF V600E Dabrafenib + Trametinib follicular thyroid carcinoma sensitive detail...
MLH1 negative Pembrolizumab follicular thyroid carcinoma sensitive detail...
MSH6 negative Pembrolizumab follicular thyroid carcinoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01723202 Phase II Dabrafenib + Trametinib Dabrafenib Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer Unknown status USA 0
NCT02145143 Phase 0 Vemurafenib Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study Active, not recruiting USA 0
NCT02152995 Phase II Trametinib Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer Active, not recruiting USA 0
NCT02211222 Phase I Lenvatinib An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer Approved for marketing USA 0
NCT02393690 Phase II Selumetinib Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer Completed USA 0
NCT02456701 Phase I CDX-3379 + Vemurafenib Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379 Completed USA 0
NCT02702388 Phase II Lenvatinib Phase 2 Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 20 mg or 14 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile Completed USA | SWE | ROU | POL | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CAN | BEL | AUS 2
NCT02973997 Phase II Lenvatinib + Pembrolizumab Pembrolizumab and Lenvatinib in Treating Metastatic or Recurrent Differentiated Thyroid Cancer That Cannot Be Removed by Surgery Completed USA 0
NCT03215095 Phase I Durvalumab RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers Active, not recruiting USA 0
NCT03244956 Phase II Trametinib Dabrafenib + Trametinib Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer (MERAIODE) Unknown status FRA 0
NCT03732495 Phase II Denosumab + Lenvatinib Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas (LENVOS) Unknown status FRA 0
NCT03753919 Phase II Durvalumab + Tremelimumab Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial (DUTHY) Terminated ESP 0
NCT03914300 Phase II Cabozantinib + Ipilimumab + Nivolumab Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer Active, not recruiting USA 0
NCT04321954 Phase II Lenvatinib Lenvatinib in Locally Advanced Invasive Thyroid Cancer Recruiting USA 0
NCT04462471 Phase I Copanlisib + Vemurafenib Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers Completed USA 0
NCT05006794 Phase I GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies Recruiting USA | ISR 0
NCT05620134 Phase Ib/II JK08 A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer Active, not recruiting ESP | BEL 0
NCT05660954 Phase II Cabozantinib Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer. (CABOTHYROID) Active, not recruiting ESP 0
NCT06007924 Phase II Defactinib + RO5126766 A Study of Avutometinib and Defactinib in People With Thyroid Cancer Recruiting USA 0
NCT06440850 Phase II Cobimetinib + Vemurafenib Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation Recruiting USA 0